India's ambition to become a global medical devices powerhouse moved from policy paper to boardroom on Saturday, August 8, 2026, when Union Health Minister J. P. Nadda chaired a CEO Roundtable at the India Medical Device Conference 2026 in New Delhi, bringing top industry leaders and senior government officials to the same table. Nadda described the session as a 'holistic' conversation spanning innovation, regulatory excellence, domestic manufacturing, value chains, market access, and exports — the full stack of what it would take to plant India's flag as a global MedTech hub. 'The Government remains committed to working closely with industry to build a competitive, innovation-driven and globally integrated MedTech ecosystem,' he said, crediting the push to Prime Minister Narendra Modi's leadership.

Why this roundtable lands at a critical moment

The stakes are not abstract. Historically, India has imported over 70–80 per cent of its medical devices — a dependency that inflates hospital costs, strains foreign exchange, and leaves the healthcare system exposed to global supply shocks. Every conversation in that conference room is, in effect, a conversation about fixing that number. The policy scaffolding is already up. The Medical Devices Rules, 2017 created a dedicated regulatory framework, separating devices from drugs for the first time. The Production Linked Incentive (PLI) scheme for medical devices, approved in 2020 with an outlay of Rs 3,420 crore, was designed to pull investment into domestic production. And the National Medical Devices Policy, 2023 tied these threads together with explicit targets for manufacturing scale-up, research, and export competitiveness.

From Atmanirbhar Bharat to a global export play

What makes the 2026 conference notable is the shift in ambition. Early Atmanirbhar Bharat messaging was largely defensive — reduce imports, build resilience. The framing at this roundtable is offensive: position India not just as a self-sufficient market but as a supplier to the world. Regulatory harmonisation and value chain integration — both flagged by Nadda — are the two levers that turn a domestic manufacturing story into an export story. Getting Indian device standards recognised internationally, and embedding Indian suppliers into global procurement chains, is the harder, longer work that follows the PLI cheques. The medical device sector sits at the intersection of health policy, industrial policy, and trade policy — which is precisely why a Health Minister who also holds the Chemicals and Fertilizers portfolio is well-placed to drive it. Whether Saturday's roundtable produces revised PLI incentives, new export targets, or regulatory reform announcements will become clear in the months ahead. The direction, however, was unmistakable.